title: [Organ toxicity of medicinal tumor therapy: morphological correlates].
abstract: CLINICAL/METHODOLOGICAL ISSUE: In antineoplastic chemotherapy classical cytostatic drugs are increasingly being supplemented by antibodies and so-called targeted therapies. In addition to the antineoplastic effect and general intolerance quite characteristic morphological changes can often be found and identified by the radiologist. The distinction between findings indicating side effects versus tumor progression or an infectious etiology is essential.
  Classical antineoplastic chemotherapy interacts with DNA and RNA synthesis, DNA repair or the mitosis process. In contrast modern targeted anticancer therapies act at the level of signal transduction pathways.Localized, organ-related changes are related to the metabolic characteristics of organs or anatomical features such as the properties of the local blood-tissue barrier. Toxicity associated findings often resemble fulminant tumor progression.
  
  
  RESULTS
  In new targeted anti-cancer therapies toxicity often occurs in a non-cumulative way; therefore, morphological changes are often precursors of the manifestation of clinical toxicity.
  
  
  CONCLUSIONS
  Oncological radiology requires increasingly active interdisciplinary dialogue in order to delineate morphological correlates of organ toxicity against tumor progression and initiate appropriate therapeutic measures.
authors.affiliation: Diagnostische und Interventionelle Radiologie, Universitätsklinik Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland. oliver.sedlaczek@med.uni-heidelberg.de
authors.forename: O
authors.initials: O
authors.lastname: Sedlaczek
authors.forename: C
authors.initials: C
authors.lastname: Grüllich
authors.forename: M
authors.initials: M
authors.lastname: Röthke
authors.forename: H-P
authors.initials: HP
authors.lastname: Schlemmer
authors.forename: H-U
authors.initials: HU
authors.lastname: Kauczor
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003952:Diagnostic Imaging / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care / Q000639:trends; D011871:Radiology / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references.citation: J Oncol. 2009;2009:567486
references.pmid: 19424511
references.citation: Am J Med. 2004 Apr 15;116(8):546-54
references.pmid: 15063817
references.citation: Arch Surg. 2003 Jan;138(1):68-75
references.pmid: 12511155
references.citation: Rofo. 2004 Sep;176(9):1245-50
references.pmid: 15346258
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: Dig Dis Sci. 2008 Jan;53(1):217-9
references.pmid: 17530401
references.citation: J Clin Oncol. 1997 Aug;15(8):2800-6
references.pmid: 9256122
references.citation: Immunopharmacology. 1997 Oct;37(2-3):117-32
references.pmid: 9403331
references.citation: Pharmacol Rev. 2004 Jun;56(2):185-229
references.pmid: 15169927
references.citation: Digestion. 2001;64(2):128-32
references.pmid: 11684828
references.citation: Transplant Proc. 2001 Nov-Dec;33(7-8):3283-4
references.pmid: 11750405
references.citation: Semin Oncol. 2006 Feb;33(1):98-105
references.pmid: 16473648
references.citation: Expert Opin Drug Saf. 2008 Nov;7(6):703-16
references.pmid: 18983217
references.citation: N Engl J Med. 1991 Mar 21;324(12):808-15
references.pmid: 1997853
references.citation: Mayo Clin Proc. 2007 Apr;82(4):521
references.pmid: 17418082
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5467; author reply 5467-8
references.pmid: 17135651
references.citation: Cancer Invest. 1999;17(3):201-5
references.pmid: 10099659
references.citation: J Comput Assist Tomogr. 1998 Nov-Dec;22(6):992-4
references.pmid: 9843246
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1405-12
references.pmid: 19224857
references.citation: Med Pediatr Oncol. 1988;16(3):216-9
references.pmid: 3164090
references.citation: J La State Med Soc. 2004 May-Jun;156(3):143-4
references.pmid: 15233387
references.citation: Am J Med. 1977 Feb;62(2):200-8
references.pmid: 835599
references.citation: Cancer Treat Rep. 1978 Jun;62(6):955-61
references.pmid: 352510
references.citation: AJR Am J Roentgenol. 2001 Dec;177(6):1319-23
references.pmid: 11717075
references.citation: Drugs. 2003;63(15):1549-63
references.pmid: 12887262
references.citation: Oncologist. 2007 Dec;12(12):1443-55
references.pmid: 18165622
references.citation: Gastrointest Radiol. 1983;8(1):71-3
references.pmid: 6832541
references.citation: Eur J Cancer. 2006 Aug;42(12):1875-80
references.pmid: 16806903
references.citation: Eur J Cancer. 2009 Sep;45 Suppl 1:332-42
references.pmid: 19775629
references.citation: Chest. 2008 Feb;133(2):528-38
references.pmid: 18252919
references.citation: Am J Clin Nutr. 2007 Aug;86(2):285-300
references.pmid: 17684197
references.citation: JAMA. 1991 Sep 25;266(12):1672-7
references.pmid: 1886191